Interreader Agreement with Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection: A Systematic Review and Meta-Analysis

Abstract

Purpose:We evaluated interreader agreement with PI-RADS® (Prostate Imaging Reporting and Data System) version 2 for detection of prostate cancer.Materials and Methods:We searched MEDLINE®, Embase® and the Cochrane Library between 2015 and June 3, 2019 to identify original research reporting interreader agreement in the use of PI-RADS version 2. Quality of the retrieved studies was assessed by 2 independent reviewers using the Guidelines for Reporting Reliability and Agreement Studies. Pooled for PI-RADS version 2 was calculated, and a head-to-head comparison with version 1 was performed for the available studies. Subgroup analysis was performed according to zonal anatomy (peripheral or transitional zone), cutoff value (4 or higher, or 3 or higher) and specific imaging sequences (T2-weighted, diffusion-weighted and dynamic contrast enhanced). Meta-regression analysis was performed to assess the cause of study heterogeneity.Results:A total of 30 studies (4,095 patients) were included. Pooled of PI-RADS version 2 was 0.61 (95% CI 0.55-0.67). In 4 studies evaluating head-to-head comparisons PI-RADS versions 1 and 2 showed similar pooled values (0.61, 95% CI 0.33-0.90 vs 0.68, 95% CI 0.57-0.79; p=0.61). Substantial interreader agreement was noted with a cutoff of 4 or higher (=0.61) and moderate agreement was observed with a cutoff of 3 or higher (=0.57), peripheral zone (=0.64), transitional zone (=0.49) and the 3 magnetic resonance imaging sequences ( 0.42-0.58). Difference in reader experience was the single significant factor affecting study heterogeneity (p=0.01).Conclusions:PI-RADS version 2 provides substantial interreader agreement in overall scoring in patients with suspicious prostate cancer, with a similar level of agreement to version 1.